Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL16339180 | 0.95 | ENPP2 (0.45) | ENPP2SIGMAR1CCR6PAX8HDAC1 | |
| Sulfurous Acid SCHEMBL1774500 | 0.95 | ENPP2 (0.45) | ENPP2SIGMAR1CCR6PAX8HDAC1 | |
| SCHEMBL1761228 | 0.85 | CCR6 (0.41) | ENPP2SIGMAR1CCR6PAX8NPC1 | |
| SCHEMBL70301 | 0.83 | CCR6 (0.55) | SIGMAR1CCR6PAX8ALDH1A1KMT2A | |
| SCHEMBL7534061 | 0.79 | CCR6 (0.51) | SIGMAR1CCR6PAX8ALDH1A1MEN1 | |
| Bicarbonate SCHEMBL7273519 | 0.79 | SIGMAR1 (0.53) | ENPP2SIGMAR1ALDH1A1EPHX1MEN1 | |
| SCHEMBL1773629 | 0.79 | SIGMAR1 (0.43) | ENPP2SIGMAR1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL11988482 | 0.79 | CCR5 (0.45) | ENPP2SIGMAR1CCR6PAX8HDAC1 | |
| SCHEMBL19525612 | 0.79 | SIGMAR1 (0.55) | ENPP2SIGMAR1ALDH1A1L3MBTL1 | |
| SCHEMBL19382504 | 0.78 | CCR6 (0.50) | ENPP2SIGMAR1CCR6PAX8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132204-B1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE INC (US) | 2013-01-23 | — | — | EP | claimed |
| EP-2132204-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | Theravance, Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| WO-2008106159-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | claimed |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-01-28 | — | — | US | disclosed |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-7622508-B2 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2009029256-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-03-05 | — | — | US | disclosed |
| WO-2008106159-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106159-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308966-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | ENPP2 2538/4885SIGMAR1 6/4885CCR6 377/4885 |
| US-20210024515-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | ENPP2 2538/4885SIGMAR1 6/4885CCR6 377/4885 |
| US-10377751-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | ENPP2 2538/4885SIGMAR1 6/4885CCR6 377/4885 |
| US-10426766-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | OPRM1, SIGMAR1, OPRD1 | ENPP2 775/4885SIGMAR1 2/4885CCR6 526/4885 |
| US-10745394-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | ENPP2 2538/4885SIGMAR1 6/4885CCR6 377/4885 |
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | ENPP2 2538/4885SIGMAR1 6/4885CCR6 377/4885 |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | OPRM1, SIGMAR1, OPRD1 | ENPP2 749/4885SIGMAR1 2/4885CCR6 514/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | ENPP2 2538/4885SIGMAR1 6/4885CCR6 377/4885 |
| US-20070219278-A1 | 3-Endo-(8-{2-[cyclohexylmethyl-(2-hydroxyacetyl)-amino]-ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-benzamide; for treating condition associated with mu opioid receptor activity, e.g. a disorder of reduced motility of gastrointestinal tract such as opioid-induced bowel dysfunction and post-operative ileus | OPRM1, OPRD1, OGFR | ENPP2 2534/4885SIGMAR1 6/4885CCR6 445/4885 |
| US-20090062333-A1 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | ENPP2 2423/4885SIGMAR1 6/4885CCR6 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.